Sun-145 Scenario of CKD in Developing Countries: A Single Center Experience

Abstract

an operation was performed-allograft of a donor kidney (donor is the patient's sister), however, a month later an early allograft rejection was noted. The results of a molecular genetic study from 21.08.2013 at the Mayo Clinic Hyperoxaluria Center (USA) revealed mutation 1: c.33_34insC, p.P11fs33X, mutation 2: c.33_34insC, p.P11fs33X, which corresponds to type I hyperoxaluria. In the spring of 2014, the patient was treated at the Fortis Memorial Research Institute clinic (Gurugram, India), and on 20.08.2014 despite the indication of immunogenetic data and the need for kidney and liver transplantation, a second kidney transplantation was performed in a hospital in India (donor is the father of the child) The postoperative period proceeded with complications. The patient was discharged from a clinic in India to continue treatment at the place of residence. In admission to the Center of Nephrology and ECDofUC, the condition was regarded as very severe due to multiple organ failure, decompensation of all vital functions, due to the progression of type 1 hyperoxaluria. Despite ongoing therapeutic measures, the child died. Cause of death: Progressive multiple organ failure: cardiovascular failure, respiratory failure, renal failure. Conclusions: The leading manifestations of primary type 1 hyperoxaluria in this case were: the development of ESRD with urolithiasis, kindred marriages, cases of urolithiasis with a terminal outcome in the family, data from a molecular diagnostic study revealing a characteristic gene mutation. Early diagnosis, simultaneous liver and kidney transplantation optimizes the prognosis for this pathology.